Airsupra is owned by Bond.
Airsupra contains Albuterol Sulfate; Budesonide.
Airsupra has a total of 1 drug patent out of which 0 drug patents have expired.
Airsupra was authorised for market use on 10 January, 2023.
Airsupra is available in aerosol, metered;inhalation dosage forms.
Airsupra can be used as as-needed treatment or prevention of bronchoconstriction and reduction of the risk of exacerbations in patients with asthma 18 years of age and older.
The generics of Airsupra are possible to be released after 28 May, 2030.
|Patent Number||Company||Patent Title||Patent Expiry||Activity Alert|
|These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).|
|US9415009||BOND||Compositions, methods and systems for respiratory delivery of two or more active agents|| |
(7 years from now)
|New Product (NP)||Jan 10, 2026|
Drugs and Companies using ALBUTEROL SULFATE; BUDESONIDE ingredient
Market Authorisation Date: 10 January, 2023
Treatment: As-needed treatment or prevention of bronchoconstriction and reduction of the risk of exacerbations in patients with asthma 18 years of age and older
Dosage: AEROSOL, METERED;INHALATION
Korea, Republic of
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic